Page last updated: 2024-12-08

3-hydroxy-5-cholestenoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-hydroxy-5-cholestenoic acid: found in infants with coprostanicacidemia; RN given refers to (3beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3beta-hydroxycholest-5-en-26-oic acid : A steroid acid resulting from the oxidation of one of the terminal methyl groups of cholesterol to the corresponding aldehyde. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID165511
CHEBI ID81014
SCHEMBL ID5610363
MeSH IDM0093863

Synonyms (23)

Synonym
3beta-hydroxy-5-cholestenoic acid
6561-58-6
C17333
3beta-hydroxycholest-5-en-27-oic acid
3beta-hydroxy-5-cholestenoate
3-hydroxycholest-5-en-26-oic acid
3-hydroxy-5-cholesten-26-oic acid
3-hydroxy-5-cholestenoic acid
3-hcoa
cholesterol-26-carboxylic acid
(6r)-6-[(3s,8s,9s,10r,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylheptanoic acid
cholest-5-en-26-oic acid, 3-hydroxy-, (3beta)-
3beta-hydroxy-5-cholesten-26-oic acid
SCHEMBL5610363
(3beta)-hydroxycholest-5-en-26-oic acid
CHEBI:81014
3beta-hydroxycholest-5-en-26-oic acid
AKOS030240791
Q27154973
DTXSID70984186
3 beta -hydroxy-5-cholestenoic acid
3?-hydroxy-5-cholestenoic acid
PD064037

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" In this work, stable isotope labeling in combination with liquid chromatography-tandem mass spectrometry was used for untargeted profiling and relative quantification of carboxyl-containing metabolites in plasma of smokers and non-smokers."( Profiling of carboxyl-containing metabolites in smokers and non-smokers by stable isotope labeling combined with LC-MS/MS.
Chen, H; Chen, J; Fu, Y; He, Y; Hou, H; Hu, Q; Luo, Y, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Our data show that Cyp27a1-/- had increased brain Aβ42, whereas Cyp7b1-/- mice had decreased brain Aβ42 levels; however, peripheral dosing of up to 100 mg/kg CA did not affect brain Aβ levels."( Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator.
Akula, R; Ba, S; Ceballos-Diaz, C; Felsenstein, KM; Golde, TE; Hochhaus, G; Jung, JI; Koo, EH; Ladd, TB; Park, HJ; Price, AR; Ran, Y; Shapiro, G; Smithson, LA; Tang, Y, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
steroid acidAny steroid substituted by at least one carboxy group.
monocarboxylic acidAn oxoacid containing a single carboxy group.
3beta-sterolA sterol in which the hydroxy group at position 3 has beta- configuration.
cholestanoidAny steroid based on a cholestane skeleton and its derivatives.
3beta-hydroxy-Delta(5)-steroidAny 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Disorders of bile acid synthesis and biliary transport1840

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (25.00)18.7374
1990's8 (40.00)18.2507
2000's4 (20.00)29.6817
2010's3 (15.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.49 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]